Literature DB >> 1786148

Absence of HIV-1 DNA in high-risk seronegative individuals using high-input polymerase chain reaction.

T H Lee1, Z el-Amad, M Reis, M Adams, E A Donegan, T R O'Brien, A R Moss, M P Busch.   

Abstract

Evidence of frequent HIV-1 infections in antibody-negative, high-risk individuals (so-called 'silent' infections) remains controversial. To evaluate whether these discrepant results may be the consequence of intermittent detection of rare infected cells (low viral load) preceding seroconversion, we developed a modification of the polymerase chain reaction (PCR) technique which enabled analysis of 10-fold greater amounts of cellular DNA per reaction than standard PCR (2 x 10(6) rather than 0.2 x 10(6) input cells). This technique allowed consistent detection of HIV-1 provirus in two seropositive individuals who had repeatedly tested negative by standard-input PCR. However, results were negative when high-input PCR was applied to 51 specimens from 39 selected high-risk seronegative individuals. These results suggest that variations in viral load preceding or in the absence of seroconversion probably do not explain discrepant evidence regarding silent HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1786148     DOI: 10.1097/00002030-199110000-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Authors:  Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

2.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Authors:  Hiroyu Hatano; Timothy L Hayes; Viktor Dahl; Elizabeth Sinclair; Tzong-Hae Lee; Rebecca Hoh; Harry Lampiris; Peter W Hunt; Sarah Palmer; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Barbara L Shacklett; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

3.  HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.

Authors:  Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Tzong-Hae Lee; Michael P Busch; Jeffrey N Martin; Joseph M McCune; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2011-01-18       Impact factor: 9.079

4.  A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Authors:  Hiroyu Hatano; Rebecca Scherzer; Yuaner Wu; Kara Harvill; Kristinalisa Maka; Rebecca Hoh; Elizabeth Sinclair; Sarah Palmer; Jeffrey N Martin; Michael P Busch; Steven G Deeks; Priscilla Y Hsue
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

5.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

6.  Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines.

Authors:  D H Schwartz; A Mazumdar; S Winston; S Harkonen
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

7.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells.

Authors:  Hiroyu Hatano; Vivek Jain; Peter W Hunt; Tzong-Hae Lee; Elizabeth Sinclair; Tri D Do; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; Frederick Hecht; Michael P Busch; Steven G Deeks
Journal:  J Infect Dis       Date:  2012-10-22       Impact factor: 5.226

8.  HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.

Authors:  Sheila M Keating; Christopher D Pilcher; Vivek Jain; Mila Lebedeva; Dylan Hampton; Mohamed Abdel-Mohsen; Xutao Deng; Gary Murphy; Alex Welte; Shelley N Facente; Frederick Hecht; Steven G Deeks; Satish K Pillai; Michael P Busch
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

9.  Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.

Authors:  Hiroyu Hatano; Steven A Yukl; April L Ferre; Erin H Graf; Ma Somsouk; Elizabeth Sinclair; Mohamed Abdel-Mohsen; Teri Liegler; Kara Harvill; Rebecca Hoh; Sarah Palmer; Peter Bacchetti; Peter W Hunt; Jeffrey N Martin; Joseph M McCune; Russell P Tracy; Michael P Busch; Una O'Doherty; Barbara L Shacklett; Joseph K Wong; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.